An update on NMDA antagonists in depression

References

• Reiner A, Levitz J. Glutamatergic signaling in the central nervous system: ionotropic and metabotropic receptors in concert. Neuron. 2018;98(6):1080–1098.
   PubMed Web of Science ®Google Scholar
• CT L, KC Y, Lin WC. Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: evidence from clinical neuroimaging studies. Front Psychiatry. 2018;9:767.
   PubMed Web of Science ®Google Scholar
• Ohgi Y, Futamura T, Hashimoto K. Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med. 2015;15(3):206–221.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Schoepp D, Kalivas PW, et al. Translating glutamate: from pathophysiology to treatment. Sci Transl Med. 2011;3(102):102mr102.
   Web of Science ®Google Scholar
• Ulbrich MH, Isacoff EY. Rules of engagement for NMDA receptor subunits. Proc Natl Acad Sci U S A. 2008;105(37):14163–14168.
   PubMed Web of Science ®Google Scholar
• Peyrovian B, Rosenblat JD, Pan Z, et al. The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:387–404.
   PubMed Web of Science ®Google Scholar
• Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185(1):1–10.
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964.
   PubMed Web of Science ®Google Scholar
• Maeng S, Zarate CA Jr., Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63(4):349–352.
   PubMed Web of Science ®Google Scholar
• Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Toxicol Pharmacol. 1993;72(6):394–397.
   PubMedGoogle Scholar
• Poleszak E, Szewczyk B, Kedzierska E, et al. Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav. 2004;78(1):7–12.
   PubMed Web of Science ®Google Scholar
• Skolnick P, Kos T, Czekaj J, et al. Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test. Acta Neuropsychiatr. 2015;27(4):228–234.
   PubMed Web of Science ®Google Scholar
• Gordillo-Salas M, Pilar-Cuellar F, Auberson YP, et al. Signaling pathways responsible for the rapid antidepressant-like effects of a GluN2A-preferring NMDA receptor antagonist. Transl Psychiatry. 2018;8(1):84.
   PubMedGoogle Scholar
• Jimenez-Sanchez L, Campa L, Auberson YP, et al. The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression. Neuropsychopharmacology. 2014;39(11):2673–2680.
   PubMed Web of Science ®Google Scholar
• Pochwat B, Rafalo-Ulinska A, Domin H, et al. Involvement of extracellular signal-regulated kinase (ERK) in the short and long-lasting antidepressant-like activity of NMDA receptor antagonists (zinc and Ro 25–6981) in the forced swim test in rats. Neuropharmacology. 2017;125:333–342.
   PubMed Web of Science ®Google Scholar
• Refsgaard LK, Pickering DS, Andreasen JT. Investigation of antidepressant-like and anxiolytic-like actions and cognitive and motor side effects of four N-methyl-D-aspartate receptor antagonists in mice. Behav Pharmacol. 2017;28(1):37–47.
   PubMed Web of Science ®Google Scholar
• Zanos P, Piantadosi SC, Wu HQ, et al. The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/GlycineB-site inhibition. J Pharmacol Exp Ther. 2015;355(1):76–85.
   PubMed Web of Science ®Google Scholar
• Zhu WL, Wang SJ, Liu MM, et al. Glycine site N-methyl-D-aspartate receptor antagonist 7-CTKA produces rapid antidepressant-like effects in male rats. J Psychiatry Neurosci. 2013;38(5):306–316.
   PubMed Web of Science ®Google Scholar
• Manosso LM, Moretti M, Ribeiro CM, et al. Antidepressant-like effect of zinc is dependent on signaling pathways implicated in BDNF modulation. Prog Neuropsychopharmacol Biol Psychiatry. 2015;59:59–67.
   PubMed Web of Science ®Google Scholar
• Satala G, Duszynska B, Stachowicz K, et al. Concentration-dependent dual mode of Zn action at serotonin 5-HT1A receptors: in vitro and in vivo studies. Mol Neurobiol. 2016;53(10):6869–6881.
   PubMed Web of Science ®Google Scholar
• Szewczyk B, Pochwat B, Rafalo A, et al. Activation of mTOR dependent signaling pathway is a necessary mechanism of antidepressant-like activity of zinc. Neuropharmacology. 2015;99:517–526.
   PubMed Web of Science ®Google Scholar
• Szewczyk B, Poleszak E, Sowa-Kucma M, et al. The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids. 2010;39(1):205–217.
   PubMed Web of Science ®Google Scholar
• Popik P, Holuj M, Kos T, et al. Comparison of the psychopharmacological effects of tiletamine and ketamine in rodents. Neurotox Res. 2017;32(4):544–554.
   PubMed Web of Science ®Google Scholar
• Popik P, Kos T, Sowa-Kucma M, et al. Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berl). 2008;198(3):421–430.
   PubMed Web of Science ®Google Scholar
• Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475(7354):91–95.
   PubMed Web of Science ®Google Scholar
• Gideons ES, Kavalali ET, Monteggia LM. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci U S A. 2014;111(23):8649–8654.
   PubMed Web of Science ®Google Scholar
• Pochwat B, Szewczyk B, Sowa-Kucma M, et al. Antidepressant-like activity of magnesium in the chronic mild stress model in rats: alterations in the NMDA receptor subunits. Int J Neuropsychopharmacol. 2014;17(3):393–405.
   PubMed Web of Science ®Google Scholar
• Quan MN, Zhang N, Wang YY, et al. Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. Neuroscience. 2011;182:88–97.
   PubMed Web of Science ®Google Scholar
• Reus GZ, Abelaira HM, Stringari RB, et al. Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. Metab Brain Dis. 2012;27(2):175–182.
   PubMed Web of Science ®Google Scholar
• Sowa-Kucma M, Legutko B, Szewczyk B, et al. Antidepressant-like activity of zinc: further behavioral and molecular evidence. J Neural Transm (Vienna). 2008;115(12):1621–1628.
   PubMed Web of Science ®Google Scholar
• Christiansen SH, Olesen MV, Wortwein G, et al. Fluoxetine reverts chronic restraint stress-induced depression-like behaviour and increases neuropeptide Y and galanin expression in mice. Behav Brain Res. 2011;216(2):585–591.
   PubMed Web of Science ®Google Scholar
• Grippo AJ, Beltz TG, Weiss RM, et al. The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia. Biol Psychiatry. 2006;59(4):309–316.
   PubMed Web of Science ®Google Scholar
• Nowak G, Szewczyk B, Wieronska JM, et al. Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull. 2003;61(2):159–164.
   PubMed Web of Science ®Google Scholar
• Fukumoto K, Toki H, Iijima M, et al. Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther. 2017;361(1):9–16.
   PubMed Web of Science ®Google Scholar
• Li N, Liu RJ, Dwyer JM, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69(8):754–761.
   PubMed Web of Science ®Google Scholar
• Neis VB, Bettio LEB, Moretti M, et al. Acute agmatine administration, similar to ketamine, reverses depressive-like behavior induced by chronic unpredictable stress in mice. Pharmacol Biochem Behav. 2016;150–151:108–114.
   PubMed Web of Science ®Google Scholar
• Tan S, Wang Y, Chen K, et al. Ketamine alleviates depressive-like behaviors via down-regulating inflammatory cytokines induced by chronic restraint stress in mice. Biol Pharm Bull. 2017;40(8):1260–1267.
   PubMed Web of Science ®Google Scholar
• Zhang WJ, Wang HH, Lv YD, et al. Downregulation of Egr-1 expression level via GluN2B underlies the antidepressant effects of ketamine in a chronic unpredictable stress animal model of depression. Neuroscience. 2018;372:38–45.
   PubMed Web of Science ®Google Scholar
• Brachman RA, McGowan JC, Perusini JN, et al. Ketamine as a prophylactic against stress-induced depressive-like behavior. Biol Psychiatry. 2016;79(9):776–786.
   PubMed Web of Science ®Google Scholar
• Talbot JN, Geffert LM, Jorvig JE, et al. Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening. Pharmacol Biochem Behav. 2016;150-151:22–30.
   PubMed Web of Science ®Google Scholar
• Pochwat B, Szewczyk B, Kotarska K, et al. Hyperforin potentiates antidepressant-like activity of lanicemine in mice. Front Mol Neurosci. 2018;11:456.
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481–486.
   PubMed Web of Science ®Google Scholar
• Yang B, Ren Q, Ma M, et al. Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the social defeat stress model. Int J Neuropsychopharmacol. 2016;19:12.
   Web of Science ®Google Scholar
• Yang BK, Qin J, Nie Y, et al. Sustained antidepressant action of the N-methyl-D-aspartate receptor antagonist MK-801 in a chronic unpredictable mild stress model. Exp Ther Med. 2018;16(6):5376–5383.
   PubMed Web of Science ®Google Scholar
• Widman AJ, McMahon LL. Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy. Proc Natl Acad Sci U S A. 2018;115(13):E3007–E3016.
   PubMed Web of Science ®Google Scholar
• Chowdhury GM, Zhang J, Thomas M, et al. Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Mol Psychiatry. 2017;22(1):120–126.
   PubMed Web of Science ®Google Scholar
• Pham TH, Defaix C, Xu X, et al. Common neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant-like effects. Biol Psychiatry. 2018;84(1):e3–e6.
   PubMed Web of Science ®Google Scholar
• Zanos P, Thompson SM, Duman RS, et al. Convergent mechanisms underlying rapid antidepressant action. CNS Drugs. 2018;32(3):197–227.
   PubMed Web of Science ®Google Scholar
• Lepack AE, Fuchikami M, Dwyer JM, et al. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol. 2014;18:1.
   Web of Science ®Google Scholar
• Lepack AE, Bang E, Lee B, et al. Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures. Neuropharmacology. 2016;111:242–252.
   PubMed Web of Science ®Google Scholar
• Workman ER, Niere F, Raab-Graham KF. mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling. Neuropharmacology. 2013;73:192–203.
   PubMed Web of Science ®Google Scholar
• Abdallah CA, Gueorguieva LA, Goktas R, et al. an immunosupressant and mTORCI inhibitor, triples the antidepressant response rate of ketamine at 2 weks following treatment: A double-blind, placebo-controlled, cross-over, randomized clinical trail. BioRxiv, The Preprint Server for Biology, Cold Spring Harbor laboratory. 2018.
   Google Scholar
• Sutton MA, Ito HT, Cressy P, et al. Miniature neurotransmission stabilizes synaptic function via tonic suppression of local dendritic protein synthesis. Cell. 2006;125(4):785–799.
   PubMed Web of Science ®Google Scholar
• Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Res. 2018;7.
   PubMedGoogle Scholar
• Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23(4):801–811.
   PubMed Web of Science ®Google Scholar
• Tornese P, Sala N, Bonini D, et al. Chronic mild stress induces anhedonic behavior and changes in glutamate release, BDNF trafficking and dendrite morphology only in stress vulnerable rats. The rapid restorative action of ketamine. Neurobiol Stress. 2019 Apr 2;10:100160. doi: 10.1016/j.ynstr.2019.100160. eCollection 2019 Feb.
   Web of Science ®Google Scholar
• Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012;64(2):238–258.
   PubMed Web of Science ®Google Scholar
• Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116–1127.
   PubMed Web of Science ®Google Scholar
• Groves JO. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry. 2007;12(12):1079–1088.
   PubMed Web of Science ®Google Scholar
• Brown PL, Palacorolla H, Brady D, et al. Habenula-induced inhibition of midbrain dopamine neurons is diminished by lesions of the rostromedial tegmental nucleus. J Neurosci. 2017;37(1):217–225.
   PubMed Web of Science ®Google Scholar
• Li B, Piriz J, Mirrione M, et al. Synaptic potentiation onto habenula neurons in the learned helplessness model of depression. Nature. 2011;470(7335):535–539.
   PubMed Web of Science ®Google Scholar
• Yang Y, Cui Y, Sang K, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554(7692):317–322.
   PubMed Web of Science ®Google Scholar
• Tian Z, Dong C, Zhang K, et al. Lack of antidepressant effects of low-voltage-sensitive T-type calcium channel blocker ethosuximide in a chronic social defeat stress model: comparison with (R)-ketamine. Int J Neuropsychopharmacol. 2018;21(11):1031–1036.
   PubMed Web of Science ®Google Scholar
• Yang C, Shirayama Y, Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5(9):e632.
   PubMed Web of Science ®Google Scholar
• Yang C, Ren Q, Qu Y, et al. Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry. 2018;83(1):18–28.
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70(3):621–660.
   PubMed Web of Science ®Google Scholar
• Yoshii A, Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol. 2010;70(5):304–322.
   PubMed Web of Science ®Google Scholar
• Ide S, Ikekubo Y, Mishina M, et al. Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine. J Pharmacol Sci. 2017;135(3):138–140.
   PubMed Web of Science ®Google Scholar
• Qu Y, Yang C, Ren Q, et al. Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model. Sci Rep. 2017;7(1):15725.
   PubMedGoogle Scholar
• Salat K, Siwek A, Starowicz G, et al. Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: role of activity at NMDA receptor. Neuropharmacology. 2015;99:301–307.
   PubMed Web of Science ®Google Scholar
• Yang C, Kobayashi S, Nakao K, et al. AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine. Biol Psychiatry. 2018;84(8):591–600.
   PubMed Web of Science ®Google Scholar
• Zanos P, Highland JN, Stewart BW, et al. (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions. Proc Natl Acad Sci U S A. 2019;116(13):6441–6450.
   PubMed Web of Science ®Google Scholar
• Shirayama Y, Hashimoto K. Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness model: comparison with (R)-ketamine. Int J Neuropsychopharmacol. 2018;21(1):84–88.
   PubMed Web of Science ®Google Scholar
• Yang C, Qu Y, Abe M, et al. (R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol Psychiatry. 2017;82(5):e43–e44.
   PubMed Web of Science ®Google Scholar
• Zhang K, Hashimoto K. An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother. 2019;19(1):83–92.
   Web of Science ®Google Scholar
• Hashimoto K, Shirayama Y. What are the causes for discrepancies of antidepressant actions of (2R,6R)-hydroxynorketamine? Biol Psychiatry. 2018;84(1):e7–e8.
   PubMed Web of Science ®Google Scholar
• Lumsden EW, Troppoli TA, Myers SJ, et al. Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function. Proc Natl Acad Sci U S A. 2019;116(11):5160–5169.
   PubMed Web of Science ®Google Scholar
• Fukumoto K, Fogaca MV, Liu RJ, et al. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine. Proc Natl Acad Sci U S A. 2019;116(1):297–302.
   PubMed Web of Science ®Google Scholar
• Liu RJ, Lee FS, Li XY, et al. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry. 2012;71(11):996–1005.
   PubMed Web of Science ®Google Scholar
• Wray NH, Schappi JM, Singh H, et al. NMDAR-independent, cAMP-dependent antidepressant actions of ketamine. Mol Psychiatry. 2018.
   Google Scholar
• Chou D, Peng HY, Lin TB, et al. (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray. Neuropharmacology. 2018;139:1–12.
   PubMed Web of Science ®Google Scholar
• Yao N, Skiteva O, Zhang X, et al. Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit. Mol Psychiatry. 2018;23(10):2066–2077.
   PubMed Web of Science ®Google Scholar
• Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015;(9):CD011612. DOI: 10.1002/14651858.CD011612.pub2
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354.
   PubMed Web of Science ®Google Scholar
• DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71(12):1605–1611.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr., Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864.
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793–802.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr., Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939–946.
   PubMed Web of Science ®Google Scholar
• Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522–526.
   PubMed Web of Science ®Google Scholar
• Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681–688.
   PubMed Web of Science ®Google Scholar
• Lally N, Nugent AC, Luckenbaugh DA, et al. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4(10):e469. mGluR.
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):2475–2483.
   PubMed Web of Science ®Google Scholar
• Aan Het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–145.
   PubMed Web of Science ®Google Scholar
• Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013;27(5):444–450.
   PubMed Web of Science ®Google Scholar
• Diamond PR, Farmery AD, Atkinson S, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014;28(6):536–544.
   PubMed Web of Science ®Google Scholar
• Kadriu B, Musazzi L, Henter ID, et al. Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments. Int J Neuropsychopharmacol. 2019;22(2):119–135.
   PubMed Web of Science ®Google Scholar
• Short B, Fong J, Galvez V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65–78.
   PubMed Web of Science ®Google Scholar
• Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19(6):370–380.
   PubMed Web of Science ®Google Scholar
• Yamaguchi JI, Toki H, Qu Y, et al. (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice. Neuropsychopharmacology. 2018;43(9):1900–1907.
   PubMed Web of Science ®Google Scholar
• Zhang K, Toki H, Fujita Y, et al. Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model. Psychopharmacology (Berl). 2018;235(11):3177–3185.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Jan 3]. Available from:https://www.realwire.com/releases/ATAI-Life-ScienceS-acquireS-majority-stake-in-Perception-Neuroscience
   Google Scholar
• FDA briefing document psychopharmacologic drugs advisory committee (PDAC)and drug safety and risk management (DSaRM) advisory committee meeting, 2019 Feb 12; Available from:https://www.fda.gov/media/121376/download
   Google Scholar
• Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016;80(6):424–431.
   PubMed Web of Science ®Google Scholar
• [cited 2016 Aug 16]. Available from:https://www.jnj.com/media-center/presS-releases/esketamine-recieveS-breakthrough-therapy-designation-from-uS-food-and-drug-administration-foR-majoR-depressive-disordeR-with-imminent-risk-of-suicide
   Google Scholar
• Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):139–148.
   PubMed Web of Science ®Google Scholar
• Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175(7):620–630.
   PubMed Web of Science ®Google Scholar
• Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–438.
   PubMed Web of Science ®Google Scholar
• Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system–too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699–723.
   PubMed Web of Science ®Google Scholar
• Amidfar M, Khiabany M, Kohi A, et al. Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. J Clin Pharm Ther. 2017;42(1):44–50.
   PubMed Web of Science ®Google Scholar
• Omranifard V, Shirzadi E, Samandari S, et al. Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study. J Res Med Sci. 2014;19(6):525–530.
   PubMed Web of Science ®Google Scholar
• Smith EG, Deligiannidis KM, Ulbricht CM, et al. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(10):966–973.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr., Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153–155.
   PubMed Web of Science ®Google Scholar
• Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol. 2007;30(3):136–144.
   PubMed Web of Science ®Google Scholar
• Muhonen LH, Lonnqvist J, Juva K, et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry. 2008;69(3):392–399.
   PubMed Web of Science ®Google Scholar
• Amidfar M, Reus GZ, Quevedo J, et al. The role of memantine in the treatment of major depressive disorder: clinical efficacy and mechanisms of action. Eur J Pharmacol. 2018;827:103–111.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr., Mathews D, Ibrahim L, et al. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry. 2013;74(4):257–264.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Smith MA, Pathak S, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014;19(9):978–985.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Johnson MR, Khan A, et al. Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo-controlled study. Neuropsychopharmacology. 2017;42(4):844–853.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology. 2015;40(2):259–267.
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28(6):631–637.
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Diaz Granados N, Jolkovsky L, et al. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012;32(4):551–557.
   PubMed Web of Science ®Google Scholar
• Bruning JB, Murillo AC, Chacon O, et al. Structure of the Mycobacterium tuberculosis D-alanine: D-alanineligase, a target of the antituberculosis drug D-cycloserine. Antimicrob Agents Chemother. 2011;55(1):291–301.
   PubMed Web of Science ®Google Scholar
• Lench AM, Robson E, Jones RS. differential effects of D-cycloserine and ACBC at NMDA receptors in the rat entorhinal cortex are related to efficacy at the Co-agonist binding site. PLoS One. 2015;10(7):e0133548.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Gelfin Y, et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord. 2006;93(1–3):239–243.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Gelfin G, Bloch B, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol. 2013;16(3):501–506.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Halberstam B, Gangwisch J. Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression. J Clin Psychiatry. 2015;76(6):737–738.
   PubMed Web of Science ®Google Scholar
• Huang CC, Wei IH, Huang CL, et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry. 2013;74(10):734–741.
   PubMed Web of Science ®Google Scholar
• Salituro FG, Tomlinson RC, Baron BM, et al. Enzyme-activated antagonists of the strychnine-insensitive glycine/NMDA receptor. J Med Chem. 1994;37(3):334–336.
   PubMed Web of Science ®Google Scholar
• Ragguett RM, Rong C, Kratiuk K, et al. Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date. Expert Opin Investig Drugs. 2019;28(2):113–119.
   PubMed Web of Science ®Google Scholar
• Allergan’s rapastinel receives FDA breakthrough therapy designation for adjunctive treatment of major depressive disorder (MDD). 2016. Available from:https://www.allergan.com/news/news/thomsonreuters/allergan-S-rapastinel-receiveS-fda-breakthrough-th.
   Google Scholar
• Available from[cited 2019 Mar 6].:https://www.allergan.com/news/news/thomson-reuters/allergan-announceS-phase-3-resultS-foR-rapastinel.
   Google Scholar
• Szewczyk B, Szopa A, Serefko A, et al. The role of magnesium and zinc in depression: similarities and differences. Magnes Res. 2018;31(3):78–89.
   PubMed Web of Science ®Google Scholar
• Mrazek DA, Hornberger JC, Altar CA, et al. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr Serv. 2014;65(8):977–987.
   PubMed Web of Science ®Google Scholar